XML 52 R39.htm IDEA: XBRL DOCUMENT v3.25.1
Income Taxes (Tables)
12 Months Ended
Dec. 31, 2024
Income Taxes  
Schedule of Components of Income (Loss) Before Income Taxes

Year Ended December 31, 

(in thousands)

    

2024

    

2023

    

2022

Domestic

$

28,507

$

(238,272)

$

(291,746)

Foreign

 

 

 

(8)

Total

$

28,507

$

(238,272)

$

(291,754)

Schedule of Income Tax Provision (Benefit)

Year Ended December 31, 

(in thousands)

    

2024

    

2023

    

2022

Current:

 

  

 

  

 

  

Federal

$

$

$

State

 

 

 

Foreign

 

 

 

Subtotal

$

$

$

 

  

 

  

 

  

Deferred:

 

  

 

  

 

  

Federal

$

$

(380)

$

State

 

 

 

Foreign

 

 

 

Subtotal

$

$

(380)

$

 

  

 

  

 

  

Income tax provision (benefit)

$

$

(380)

$

Schedule of Reconciliation of the Statutory United States Federal Rate to the Company's Effective Tax Rate

Year Ended December 31, 

 

    

2024

    

2023

    

2022

  

Percent of pre-tax income:

 

  

 

  

 

  

United States federal statutory income tax rate

 

21.0

%  

21.0

%  

21.0

%

State taxes, net of federal benefit

 

2.8

 

(1.2)

 

1.7

Permanent items

(1.7)

 

 

(0.1)

Research and development credit

 

(23.9)

 

0.9

 

1.8

Stock-based compensation costs

31.4

(3.5)

(2.3)

Sale Transactions

1.8

Other

 

5.6

 

0.7

 

Change in valuation allowance

(37.0)

 

(17.7)

 

(22.1)

Effective income tax rate

 

%  

0.2

%  

%

Schedule of Components of the Company's Net Deferred Tax Assets (Liabilities)

December 31, 

(in thousands)

    

2024

    

2023

Deferred tax assets:

Net operating loss carryforwards

$

158,090

$

170,402

Research and development credits

 

72,031

 

65,225

Depreciation and amortization

 

28,861

 

37,211

Stock-based compensation

 

26,814

 

30,370

Sales related accruals

 

39,966

 

38,474

Other accruals

 

42,537

 

42,480

Capitalized research and development

50,850

46,062

Total gross deferred tax assets

 

419,149

 

430,224

Valuation allowance

 

(412,833)

 

(423,385)

Total net deferred tax assets

6,316

6,839

Deferred tax liabilities:

Right-of-use asset

 

(1,004)

 

(1,538)

In-process research and development

 

(6,414)

 

(6,403)

Total deferred tax liabilities

 

(7,418)

 

(7,941)

Net deferred tax liabilities

$

(1,102)

$

(1,102)

Schedule of Reconciliation of the Company's Unrecognized Tax Benefits

Year Ended December 31, 

(in thousands)

    

2024

    

2023

    

2022

Balance at beginning of year

$

17,417

$

16,838

$

15,495

Additions based on tax positions related to current year

 

1,565

 

865

 

1,385

Additions (reductions) for tax positions of prior years

 

265

 

(286)

 

(42)

Balance at end of year

$

19,247

$

17,417

$

16,838